/PYPD
PYPD Stock - PolyPid Ltd.
Healthcare|BiotechnologyNASDAQ
$3.97+1.28%
+$0.05 (+1.28%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.60
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+126.7%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PYPD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.93 – $4.01
TARGET (TP)$9.00
STOP LOSS$3.65
RISK/REWARD1:15.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.49
52W High$4.07
52W Low$2.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | $-1,721,000 | $-1,118,000 | $-1,012,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-28,029,000 | $-22,867,000 | $-38,888,000 | $-43,145,000 | $-26,272,000 |
| Net Income | $-29,022,000 | $-23,865,000 | $-39,525,000 | $-40,713,000 | $-35,324,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-4.91 | $-16.99 | $-61.20 | $-67.80 | $-4.48 |
Company Overview
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 177.1% Upside
Now
$9
Low
$11
Average
$13
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 5th 2025 | Roth Capital | Initiation | Buy | $9 |
| June 2nd 2025 | H.C. Wainwright | Resumed | Buy | $11 |
| January 28th 2025 | Rodman & Renshaw | Initiation | Buy | $13 |
Earnings History & Surprises
PYPDBeat Rate
61%
Last 18 quarters
Avg Surprise
-241.3%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q1 24
-82.9%
$-3.97vs$-2.17
Q2 24
+30.1%
$-1.37vs$-1.96
Q3 24
+17.2%
$-1.25vs$-1.51
Q4 24
-14.0%
$-1.22vs$-1.07
Q1 25
-25.6%
$-1.13vs$-0.90
Q2 25
+12.5%
$-0.70vs$-0.80
Q3 25
-47.2%
$-0.78vs$-0.53
Q4 25
+31.5%
$-0.37vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.54 | $-0.37 | +31.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.53 | $-0.78 | -47.2% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.80 | $-0.70 | +12.5% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $-0.90 | $-1.13 | -25.6% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-1.07 | $-1.22 | -14.0% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-1.51 | $-1.25 | +17.2% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-1.96 | $-1.37 | +30.1% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $-2.17 | $-3.97 | -82.9% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-3.62 | $-3.40 | +6.1% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.31 | $-3.90 | -1158.1% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.26 | $-8.41 | -3134.6% | ✗ MISS |
Q1 2023 | Feb 8, 2023 | $-10.51 | $-9.61 | +8.6% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-15.62 | $-14.41 | +7.7% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-20.72 | $-18.32 | +11.6% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-20.42 | $-18.92 | +7.3% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $-15.62 | $-21.32 | -36.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-19.82 | $-15.92 | +19.7% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-17.42 | $-16.82 | +3.4% | ✓ BEAT |
Latest News
PolyPid Appoints Brooke Story As Board Chairman, Effective Dec. 11
➖ NeutralBenzinga•Dec 16, 2025, 01:33 PM
PolyPid Receives FDA Pre-NDA Meeting Minutes For D-PLEX₁₀₀ Supporting NDA Submission
📈 PositiveBenzinga•Dec 3, 2025, 01:31 PM
Roth Capital Maintains Buy on PolyPid, Lowers Price Target to $9
📈 PositiveBenzinga•Nov 13, 2025, 04:38 PM
PolyPid Q3 Cash & Equivalents $18.8M
➖ NeutralBenzinga•Nov 12, 2025, 12:31 PM
PolyPid Q3 EPS $(0.37) Beats $(0.44) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:30 PM
PolyPid Announces That Dr. Shmuel Sharoni Will Present Topline Phase 3 Shield II Trial Results For D-PLEX₁₀₀ At The 2025 American College Of Surgeons Clinical Congress In Chicago
➖ NeutralBenzinga•Sep 30, 2025, 12:50 PM
Frequently Asked Questions about PYPD
What is PYPD's current stock price?
PolyPid Ltd. (PYPD) is currently trading at $3.97 per share. The stock has moved +1.28% today.
What is the analyst price target for PYPD?
The average analyst price target for PYPD is $9.00, based on 1 analyst.
What sector is PolyPid Ltd. in?
PolyPid Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PYPD's market cap?
PolyPid Ltd. has a market capitalization of $0.04 billion, making it a small-cap company.
Does PYPD pay dividends?
No, PolyPid Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
VERU
Veru Inc.
$2.32
Mkt Cap: $0.0B
Explore stocks similar to PYPD for comparison